DarioHealth Earnings Call: Growth Promise, Execution Test

DarioHealth ((DRIO)) has held its Q4 earnings call. Read on for the main highlights of the call.

DarioHealth’s latest earnings call painted a cautiously optimistic picture, blending clear commercial momentum with lingering execution and funding risks. Management highlighted record new deals, expanding margins and sharply lower operating expenses, yet these positives were tempered by a double‑digit revenue decline, a thin cash cushion and heavy reliance on future ramp‑up to hit breakeven targets.

Record New Business Wins

DarioHealth reported its strongest year ever for new business, signing 85 agreements in 2025 against a target of just 4. Management stressed that average contract sizes are now 2x–10x larger than past deals, signaling a step‑change in the company’s ability to win sizable, enterprise‑level customers rather than small pilot programs.

Contracted and Late-Stage ARR

The company has secured $12.9 million in contracted and late‑stage annual recurring revenue from 2025 wins, which is slated to translate into revenue primarily in 2026 and 2027. This backlog offers visibility into future growth, but investors will need to watch how quickly these contracts move from paper to active, revenue‑generating deployments.

Expanded Pipeline and Distribution Reach

DarioHealth’s commercial pipeline has expanded to $122 million, now framed as a combined opportunity for 2026 and 2027. Through its distribution partners and curated marketplaces, the company claims access to more than 160 million covered lives, which management views as the foundation for scaling revenue efficiently over the next several years.

Sequential Revenue Growth and Q4 Recovery

After a tough stretch, the company returned to sequential revenue growth, posting $5.2 million in Q4 2025 revenue. Management expects revenue growth to build through 2026, with the second half of the year projected to deliver the strongest acceleration as large channel deals begin to meaningfully contribute.

Improved Gross Margins

Profitability metrics moved in the right direction as GAAP gross margin improved from 49% in 2024 to 57% in 2025, an eight‑point gain. The core B2B2C ARR business has maintained roughly 80% non‑GAAP gross margin for two years, underscoring favorable unit economics as the mix shifts toward scalable, software‑driven offerings.

Substantial Operating Expense Cuts

DarioHealth continued its cost‑discipline drive, cutting full‑year total operating expenses by 31% to $49.3 million. On a non‑GAAP basis, operating expenses fell 26%, or $13.6 million, to $38.6 million year over year, suggesting the company has reset its expense base closer to a sustainable level without halting growth initiatives.

Operating Loss and Cash Burn Trends

These cost actions translated into better bottom‑line performance, with full‑year GAAP operating loss improving by $21.0 million, a 37% reduction, and non‑GAAP operating loss improving by $9.6 million, or 29%. Net cash used in operating activities declined 33%, from $38.6 million in 2024 to $25.9 million in 2025, indicating progress but not yet a self‑funding model.

Strategic Partners and Contract Extensions

Management highlighted meaningful wins and deployments with major payers and partners, including Florida Blue, UnitedHealthcare and Premera Blue Cross. The company is finalizing multiyear extensions with Aetna and Centene and has been selected as a preferred or in‑network partner for Solara Health, with inclusion in an upcoming rollout across the HCSC footprint.

Data and AI as Competitive Moat

DarioHealth emphasized its proprietary DarioIQ AI engine, which is trained on more than 13 billion real data points spanning chronic condition management. Executives underscored the value of owning vertically integrated data and pointed to over 100 peer‑reviewed studies as evidence of clinical credibility that can differentiate the platform in payer and employer negotiations.

Financial Targets and Breakeven Ambitions

Looking ahead, management aims to further narrow non‑GAAP operating loss by about 30% in 2026 and targets cash‑flow breakeven by mid‑2027. They estimate that reaching breakeven will require revenue in the range of roughly $38–42 million, implying meaningful top‑line growth from current levels alongside continued cost discipline.

Year-Over-Year Revenue Decline

Despite strategic progress, full‑year revenue fell to $22.4 million in 2025 from $27.0 million in 2024, a 17% decline. Management attributed this shortfall primarily to the non‑renewal of a single legacy client associated with the Twill acquisition, highlighting how one contract can still sway overall results.

Concentration and Timing Risk

The legacy client non‑renewal exposed concentration and timing risks in DarioHealth’s revenue base, even if framed as a one‑time event. Executives acknowledged that the business remains sensitive to large customer decisions and stressed the importance of diversifying revenue as new channel deals begin to scale.

Cash Position and Remaining Burn

The company ended 2025 with $26.0 million in cash and short‑term deposits against $25.9 million of net cash used in operating activities during the year. While cash burn is improving, the current balance leaves limited margin for error, increasing pressure to execute on the revenue ramp and maintain tight control over spending.

Pipeline Timing and Revenue Recognition Lag

A key theme was timing: the $122 million pipeline and recent channel wins are large, but many are still in onboarding or implementation stages. Management cautioned that revenue from these agreements will ramp predominantly in 2026 and 2027, creating a lag that may keep near‑term reported revenue below the potential implied by the pipeline size.

Go-to-Market Shift and Execution Needs

DarioHealth is shifting its go‑to‑market strategy toward one‑to‑many distribution through payer ecosystems and curated networks, rather than purely direct employer sales. This model should be more scalable, but it demands investment in implementation capabilities and operational changes that could introduce short‑term volatility as the company standardizes its approach.

Breakeven Timeline and Growth Gap

To reach cash‑flow breakeven by mid‑2027, the company must grow revenue from $22.4 million in 2025 to roughly $38–42 million, a sizeable jump. Management is betting that the ramp‑up of large channel deals, combined with ongoing expense reductions, will close this growth gap, but execution risk remains central to the investment case.

Outlook and Forward-Looking Commentary

While not issuing formal guidance, DarioHealth outlined a path that leans on strong contracted ARR, a $122 million pipeline and access to more than 160 million covered lives. Management expects revenue growth to build through 2026 with the sharpest acceleration in the second half and believes additional cost controls will shrink non‑GAAP operating loss by about 30% next year on the way to mid‑2027 breakeven.

DarioHealth’s earnings call sketched a company in transition, trading near‑term revenue pressure and cash constraints for what could be a more scalable, higher‑margin model. For investors, the story now hinges on whether the record 2025 deal wins and deep payer relationships can convert into sustained revenue growth quickly enough to hit ambitious breakeven targets without tapping fresh capital.